Neurodegenerative means the progressive loss of nerve cells in the brain or spinal cord. The term breaks down into “neuro” (nerves) and “degenerative” (gradually deteriorating), and it describes a process where neurons slowly stop working, lose their connections to other cells, and eventually die. Because the human brain has very limited ability to replace lost neurons, this damage accumulates over time, leading to worsening symptoms that affect memory, movement, thinking, or some combination of all three.
What Happens Inside the Brain
The core problem in most neurodegenerative diseases is protein misfolding. Your cells constantly produce proteins that need to fold into precise three-dimensional shapes to function properly. When these proteins fold incorrectly, they clump together into sticky aggregates that the brain can’t clear away efficiently. These clumps are toxic to neurons. They disrupt the cell’s energy production, trigger inflammation, and interfere with the chemical signals neurons use to communicate with each other.
The clumping process follows a pattern sometimes called “seeding.” It starts slowly, with a few misfolded proteins forming a small cluster. Once that initial seed forms, the process accelerates exponentially as the cluster recruits more and more misfolded copies. This is one reason neurodegenerative diseases seem to creep along for years before symptoms appear, then worsen noticeably once they do.
Oxidative stress plays a role too. Cells naturally produce reactive molecules as byproducts of energy metabolism, and normally the body neutralizes them. In neurodegeneration, this balance tips. Excess reactive molecules damage cell structures and can even promote further protein misfolding, creating a feedback loop that speeds up the process.
Major Neurodegenerative Diseases
Different neurodegenerative diseases involve different misfolded proteins and strike different parts of the brain, which is why their symptoms look so different from one another.
Alzheimer’s disease is the most common, affecting an estimated 6.9 million Americans age 65 and older. Globally, more than 55 million people live with Alzheimer’s or other dementias. The hallmark proteins are amyloid-beta, which forms plaques between neurons, and tau, which tangles inside them. These changes hit the hippocampus and entorhinal cortex earliest, the brain regions responsible for forming new memories. That’s why forgetting recent conversations or misplacing things is typically the first sign.
Parkinson’s disease centers on a protein called alpha-synuclein, which clumps inside neurons in a part of the midbrain that produces dopamine. Dopamine is essential for smooth, coordinated movement, so the classic symptoms are tremor, stiffness, and slowness of movement. About 24.5% of people with Parkinson’s eventually develop dementia as well, because the damage can spread to other brain regions over time.
Amyotrophic lateral sclerosis (ALS) targets motor neurons in the spinal cord, brainstem, and frontal cortex. These are the cells that carry signals from the brain to muscles, so their loss leads to progressive muscle weakness, difficulty speaking and swallowing, and eventually the inability to breathe independently.
Huntington’s disease is caused by a specific genetic mutation: an abnormally long repeat of a DNA sequence in the huntingtin gene. About 90% of cases are inherited from a parent in an autosomal dominant pattern, meaning a single copy of the mutated gene is enough to cause the disease. The remaining 10% arise from new mutations. Huntington’s causes a combination of involuntary movements, cognitive decline, and psychiatric symptoms.
Genetics vs. Lifestyle Risk
The role of genetics varies dramatically depending on the disease. Huntington’s is almost entirely genetic. Alzheimer’s and Parkinson’s are more complicated. Most cases of both are “sporadic,” meaning they arise without a clear single-gene cause, likely driven by a combination of genetic susceptibility, aging, and environmental factors.
That said, certain genetic variants significantly increase risk. The best-known example is the APOE4 gene variant in Alzheimer’s disease. Carrying one copy roughly triples the risk in white populations, while carrying two copies can increase risk by up to 15-fold. For Parkinson’s, mutations in a gene called LRRK2 are among the most well-established genetic risk factors. Rare, fully dominant mutations in genes like APP, PSEN1, and PSEN2 essentially guarantee early-onset Alzheimer’s, but these account for a very small fraction of total cases.
How Symptoms Progress
Neurodegenerative diseases share a common trajectory: they start subtly and get worse over years or decades. In Alzheimer’s, the earliest stage is mild cognitive impairment, where a person may have noticeable memory lapses (forgetting appointments, losing the thread of a conversation) but can still manage daily life independently. As the disease advances, language, judgment, problem-solving, and personality all deteriorate. In the most severe stage, people lose the ability to sit upright, swallow, or control bladder and bowel function. Muscles may become rigid and reflexes stop responding normally.
Parkinson’s follows a different arc, starting with motor symptoms on one side of the body, often a slight tremor in one hand, before gradually becoming bilateral. Non-motor symptoms like sleep disturbances, loss of smell, and constipation can actually precede the tremor by years. ALS progresses faster than most neurodegenerative diseases, with an average survival of two to five years from diagnosis, though individual timelines vary widely.
How These Diseases Are Diagnosed
Diagnosis typically combines clinical evaluation with imaging and lab tests. For Alzheimer’s, doctors can measure specific proteins in cerebrospinal fluid (the liquid surrounding the brain and spinal cord) or use PET scans to detect amyloid plaques and tau tangles directly in a living brain. MRI scans can reveal shrinkage in the hippocampus and other vulnerable regions, and this shrinkage pattern helps distinguish Alzheimer’s from other forms of dementia.
Parkinson’s diagnosis relies more on clinical symptoms, but specialized imaging can confirm the loss of dopamine-producing neurons. For ALS, electrical tests that measure nerve and muscle function help confirm motor neuron damage. Each disease has its own diagnostic fingerprint, and biomarker-based diagnosis is becoming increasingly precise, though no single test is definitive for most of these conditions.
Current Treatment Options
For most of the history of treating neurodegenerative diseases, medications could only manage symptoms without slowing the underlying damage. That changed in 2023 and 2024, when the FDA approved two antibody-based treatments for early-stage Alzheimer’s: lecanemab (2023) and donanemab (2024). Both work by targeting and clearing amyloid plaques from the brain, and clinical trials showed they slowed cognitive decline in people with mild cognitive impairment or mild dementia. They carry risks, including brain swelling and small brain hemorrhages, and they require biomarker confirmation that amyloid plaques are present before treatment can begin.
For Parkinson’s, treatments that replace or mimic dopamine remain the standard of care and can effectively control motor symptoms for years, though they don’t stop the disease from progressing. ALS and Huntington’s have fewer treatment options, and the focus remains largely on managing symptoms and maintaining quality of life as long as possible.
Reducing Your Risk
While no lifestyle change can guarantee prevention, research consistently links cognitive and physical activity to lower rates of neurodegeneration. Studies in cognitively normal older adults have found that higher levels of lifetime cognitive activity (things like reading, puzzles, learning new skills, and social engagement across early, middle, and later life) are associated with less amyloid plaque buildup in the brain and fewer signs of damage to the brain’s white matter, the wiring that connects different regions.
Physical activity shows similar benefits. Regular exercise is linked to less white matter damage, better neural integrity, and stronger overall cognitive performance. These aren’t small, marginal effects. Both cognitive and physical activity appear to work through measurable biological pathways, preserving the structural health of the brain in ways that show up on imaging. The evidence is strongest for sustained habits across a lifetime rather than starting late, though current activity levels still made a meaningful difference in the studies that tracked them.